On April 10, ADVI Health’s senior director, federal agency engagement, and co-lead of ADVI’s Inflation Reduction Act (IRA) Center of Excellence, John Coster, was featured in Citeline’s Pink Sheet, where he discussed the cost of anti obesity drugs in Medicare and Medicaid.

In the article, “GLP-1 Drug Coverage Growing For Obesity In Medicaid, But Only For Diabetes In Medicare,” John expands on the possibility of the proposal being challenged in court.

Read more in Pink Sheet.